Neuropathic Pain and Cannabis: Cochrane Review Lacks Clear Evidence of Relief

• How much evidence. 3 works from 2023 to 2026, all listed in the table below along with the model.
• What was not demonstrated. The authors of the Cochrane review rated the certainty of evidence for most outcomes as very low, and those effects that reached statistical significance were described as clinically insignificant. In none of the three groups of preparations was it shown
• What you won’t find here. Dosage recommendations or strain indications. The choice is made by the attending physician, and cannabis flower is a raw material dispensed only by prescription.
• How to read this. The result of a study on rodents or in cell culture does not directly translate to a patient taking flower, and the column with the model indicates what the work was actually about.

What do studies say about cannabis in neuropathic pain?

There is no clear evidence that cannabis alleviates neuropathic pain by at least half. This is the result of the update of the Cochrane review published in January 2026 (PMID:41548880), which included 21 randomized double-blind studies and 2187 participants treated for two to twenty-six weeks.

The review updates the work from 2018 and divides the studied preparations into three families: those with a predominance of tetrahydrocannabinol, balanced, and those with a predominance of cannabidiol. In the first family, the risk difference for relief of at least half was 0.14, with a 95 percent confidence interval ranging from minus 0.07 to 0.37, calculated on seven studies and 534 participants. The interval includes zero, so this result does not distinguish the preparation from placebo, and the authors rated the certainty of evidence as very low.

The balanced family performed similarly. There is no clear evidence for relief of at least half for it, although these preparations raised the percentage of individuals rating their improvement as large by 0.07. The authors themselves noted that this effect is not clinically significant. For preparations with a predominance of cannabidiol, no clear evidence was demonstrated either. Three families, three times the same conclusion.

The measure on which this conclusion stands is the percentage of patients experiencing a reduction in pain by half compared to baseline. In pain studies, it is treated as a threshold for a noticeable outcome in daily functioning, not as a number convenient for calculation.

What is the difference between statistically significant and clinically significant results?

The former speaks to the probability of the case, while the latter speaks to the size of the change perceived by the patient. An effect can be statistically certain and yet so small that the patient does not notice it. On this page, the distinction is not a digression, as it precisely delineates the boundary between the three cited works.

Three works measured three different magnitudes, and all three turned out to be small. The Cochrane review reported for balanced preparations an increase of 0.07 in the percentage of individuals rating their improvement as large, after which it itself labeled it clinically insignificant. The update of the review published in Annals of Internal Medicine (PMID:41429020) measured a reduction in pain intensity of 0.78 points on a scale from zero to ten for oral preparations with a predominance of tetrahydrocannabinol and 0.54 points for extracts administered to the oral mucosa.

The work published in PLOS ONE (PMID:36716312) shows where the threshold lies. The measured reduction in chronic pain was 0.43 points on the numerical scale, and the confidence interval ranged from minus 0.72 to minus 0.15, so the result is statistically certain. However, the authors added that it does not reach the magnitude they previously accepted as minimally important, and a high risk of systematic error was present in 59 of the 65 included studies and every calculated outcome.

The distinction has practical implications. A statistically significant result only indicates that the measured difference likely did not arise from random variation. It does not say whether a patient with diabetic polyneuropathy will notice a change in walking, sleeping, or working. With a difference of half a point on a ten-point scale, the answer to the latter question is usually negative.

What strain characteristics matter here?

None, as far as we are asking about these studies. The three cited reviews grouped preparations by the ratio of both main compounds, origin, and route of administration, not by strain name. Neither the terpene profile nor the strain name was a variable that anyone analyzed or reported.

The authors of the review published in Annals of Internal Medicine themselves listed the lack of product description among the limitations of their work. They knew the ratio of tetrahydrocannabinol to cannabidiol and whether the preparation was synthetic, purified, or extractive, but they had no data on which plant the raw material came from. From such material, it is impossible to calculate whether one strain performs better than another.

A Polish pharmacy describes the raw material differently than these studies. The prescription states the Latin name of the raw material and the declared content of both compounds, while the trade name of the strain is a label from the manufacturer, not a pharmacopoeial parameter. Terpenes such as myrcene or caryophyllene may be mentioned in commercial descriptions, but none of the three discussed works calculated their contribution to analgesic action. Separate texts of this cluster gather what has been demonstrated for individual terpenes, and what has not. Evidence for spasticity in multiple sclerosis is described on a separate page, as it is the only neurological indication in which preparations with a defined composition were studied. A compilation of strains available in Polish pharmacies is conducted by a separate review.

What does the doctor decide, and what does the patient decide?

The doctor decides everything related to treatment: the indication, the preparation, the dosage, and the route of administration. The patient decides whether to undertake such treatment at all and reports to the doctor what they feel. Cannabis flower is a pharmaceutical raw material dispensed only by prescription marked with the symbol Rpw.

A prescription for flower is a prescription for a medication prepared in a pharmacy and is subject to separate regulations. It indicates the name of the raw material in Latin and the declared content of both compounds, and the term for its realization is 30 days from the date of issuance, as directly stipulated by pharmaceutical law. It cannot be issued with a deferred realization date. The pharmacy prepares the medication according to what the doctor has prescribed and has no right to substitute one strain for another.

This arrangement also explains what this page does not do. Pharmaceutical law prohibits directing advertisements for medications dispensed by prescription to the public, which is why we describe only the state of evidence and do not suggest any preparation or strain. The choice belongs to the attending physician, who knows the entire list of medications taken by the patient and their diagnosis. The formal process is described in a separate entry on obtaining a prescription in Poland.

How long does the effect last after vaporization, and how long after ingestion?

Shorter after vaporization, significantly longer after ingestion. The difference is important when reading the cited studies, as they primarily measured oral preparations and extracts administered to the oral mucosa, not inhaled raw material. The route of administration changes the course of action more than the choice of a specific strain of flower.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect wears off within two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two, and the episode lasts six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks after thirty minutes that nothing is happening and adjusts the dose will receive both doses at once. The above ranges describe the route of administration, not the strain; pharmacokinetic studies for a single cultivar have not been published.

The translation to the cited results is direct. Since a reduction in pain intensity of 0.78 points was measured for swallowed forms, and 0.54 points for aerosol on the mucosa, both numbers describe the course proper to those routes, not inhalation. Transferring such a result to vaporized raw material would require a study that is not present in this trio.

What adverse effects have been reported with cannabis use for this indication?

Primarily from the nervous system. In the Cochrane review, preparations with a predominance of tetrahydrocannabinol may have increased such events, with a risk difference of 0.25 with a range from 0.14 to 0.37. The benefit in this indication remained uncertain, and this particular harm was measured and described with a specific number.

The number comes from the Cochrane review encompassing 21 randomized double-blind studies, totaling 2187 participants, with observation lasting from two to twenty-six weeks. The systematic review from Annals of Internal Medicine, based on 25 short-term placebo-controlled studies and 2303 participants, in which neuropathic pain constituted 64 percent of cases, described a clear increase in dizziness, drowsiness, and nausea in both groups of preparations with a higher proportion of tetrahydrocannabinol.

The third work, a review with meta-analysis and sequential analysis based on 65 studies with 7017 participants, recorded the same direction: an increase in milder adverse events, without a detectable increase in severe events. The comparison thus comes out asymmetrical. On the benefit side are results that the authors themselves do not consider important for the patient, while on the harm side are measurable results.

Reports of adverse events are collected for medicinal products with a batch number, not for the strain name, so the following pertains to cannabis flower as a group of raw materials. The most commonly reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and transient worsening of short-term memory, as well as anxiety increasing with dosage, are described less frequently. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for cannabis flower in Poland do not separate them by individual products.

What cannot be read from these studies?

How cannabis works over the years, and how a single strain of flower performs. The longest of the studies included in the Cochrane review lasted twenty-six weeks, and the review from Annals of Internal Medicine included only short-term studies, from one month to half a year. This trio of works says nothing about long-term treatment.

The authors of the Cochrane review rated the certainty of evidence for most outcomes as very low, and those effects that reached statistical significance were described as clinically insignificant. In none of the three groups of preparations was it shown that cannabis provided relief of at least half more often than placebo, which is a measure that pain researchers consider a meaningful outcome for patients. The studies included medications with known dosages, not pharmacy-grade cannabis described by strain name.

There are also no comparisons between the preparations themselves. All three works compare cannabis to placebo, not one form of raw material to another, so they do not answer the question of which performs better. A fair summary thus sounds different from how it is often summarized in headlines: the evidence is weak and uncertain. A negative result in such a review means a lack of clear evidence, not evidence of absence.

Frequently Asked Questions about Cannabis and Neuropathic Pain

Do cannabis products treat neuropathic pain?

There is no clear evidence that they provide relief of at least half. The Cochrane review from January 2026 found no such evidence in any of the three families of preparations, and the certainty of evidence for most outcomes was rated as very low.

What does a statistically significant but clinically insignificant result mean?

It means that the measured difference likely did not arise from chance, but is too small for the patient to notice. This is how the authors of the Cochrane review described the increase of 0.07 in the percentage of individuals rating their improvement as large.

Does any strain of flower perform better for neuropathic pain?

This cannot be read from these studies. Preparations were grouped by the ratio of both compounds and route of administration, not by strain name, and the lack of product description was listed as a limitation by the authors of one of the works.

What adverse effects were described in these studies?

The most common are dizziness, drowsiness, and nausea. Preparations with a predominance of tetrahydrocannabinol may increase adverse events from the nervous system, with a risk difference of 0.25 in the review encompassing 21 studies.

Is cannabis flower available without a prescription?

No. Flower is a pharmaceutical raw material dispensed only by prescription marked with the symbol Rpw, and the medication is prepared by the pharmacy. The term for realization of such a prescription is 30 days from the date of issuance.

Do the results of these studies pertain to vaporization?

Only indirectly. The cited reviews primarily measured oral preparations and extracts administered to the oral mucosa, so they describe the course proper to those routes of administration, not inhalation of raw material.

This material is for informational purposes only and does not replace medical advice. Cannabis flower is a pharmaceutical raw material dispensed by a doctor’s prescription in the Rpw category, and treatment decisions are made by the attending physician. The editorial text was prepared by the editorial team of ubucha.pl.